Physiopathology and prospectives for therapeutic treatment of pulmonary fibrotic state in COVID-19 patients.
Curr Res Pharmacol Drug Discov
; 2: 100056, 2021.
Article
in English
| MEDLINE | ID: covidwho-1556227
ABSTRACT
The COVID-19 global pandemic has caused about 4,30 Mln deaths. Recently the first vaccines have been licensed, representing the most powerful weapon available to stop the pandemic. The COVID-19 viral infection in the most severe cases can cause severe lung lesions with the presence of ï¬brotic tissue. Even among cured individuals, the presence of pulmonary fibrotic tissue may be the major cause of long-term complications of COVID-19 requiring antifibrotic therapeutic treatment even in the post-COVID-19 infection phase to accelerate the healing process and fully recover lung function. This article reviews the fibrogenic mechanism of SARS-CoV-2-induced viral damage and the antifibrotic treatments indicated to treat sequelae post COVID-19 infection.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Topics:
Long Covid
/
Vaccines
Language:
English
Journal:
Curr Res Pharmacol Drug Discov
Year:
2021
Document Type:
Article
Affiliation country:
J.crphar.2021.100056
Similar
MEDLINE
...
LILACS
LIS